Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 290 participants.

Also called NCT02126358

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 290 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02126358
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02126358. Randomized; quadruple masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2016-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)
Condition
Dyslipidemia
Intervention (Drug)
Gemigliptin and/or Rosuvastatin
Lead sponsor
LG Life Sciences (class: industry)

Record details

Record id
cardio:ct-nct02126358
Content hash
adc16461fd2a4f020e56bcca14f3aad276230df0d053b7953c992eddfde48f4e